ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 Q2 P&L / Income Statement

ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,290,948,000 US dollars

Cost of goods sold

298,261,000 US dollars

Gross profit (calculated)

992,687,000 US dollars

Operating expenses (calculated)

761,246,000 US dollars

Income (loss) from operations

231,441,000 US dollars

Total other expense, net

negative 53,635,000 US dollars

Income (loss) before income taxes

177,806,000 US dollars

Provision for income taxes

13,312,000 US dollars

Net income (loss)

164,494,000 US dollars

Net revenues from collaborations

47,165,000 US dollars

Royalty revenue

71,674,000 US dollars

Amvuttra - Rest of World

83,673,000 US dollars

Amvuttra - UNITED STATES

809,079,000 US dollars

Amvuttra - Europe

119,010,000 US dollars

GIVLAARI - Rest of World

7,441,000 US dollars

GIVLAARI - UNITED STATES

58,000,000 US dollars

GIVLAARI - Europe

24,323,000 US dollars

ONPATTRO - Rest of World

3,090,000 US dollars

ONPATTRO - UNITED STATES

9,863,000 US dollars

ONPATTRO - Europe

5,508,000 US dollars

OXLUMO - Rest of World

10,899,000 US dollars

OXLUMO - UNITED STATES

18,545,000 US dollars

OXLUMO - Europe

22,678,000 US dollars

Cost of collaborations and royalties

190,000 US dollars

Research and development

413,134,000 US dollars

Selling, general and administrative

347,922,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.